NCT07524257 2026-04-13
ResQ1010-NSCLC: NAI + Chemoimmunotherapy vs Chemoimmunotherapy for First-Line Advanced/Metastatic NSCLC
ImmunityBio, Inc.
Phase 3 Not yet recruiting
ImmunityBio, Inc.
Bristol-Myers Squibb
Eikon Therapeutics
Shanghai Henlius Biotech
Shanghai YingLi Pharmaceutical Co. Ltd.
Shanghai Henlius Biotech